Clinical Trials Detail

SCRI BRE 186 - Phase II Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy



Breast cancer with residual disease after treatment with a standard neoadjuvant chemotherapy regimen and surgery.


This is a non-randomized, Phase II study assessing the efficacy of eribulin in HER2-positive breast cancer patients who have residual disease after treatment with standard chemotherapy and surgery.


  • Assess the effectiveness of the drugs eribulin and trastuzumab when given to HER2-positive breast cancer patients who do not achieve pCR following standard chemotherapy and surgery.
  • To estimate the 2-year disease-free survival rate.
  • Assess the feasibility of administering 6 cycles of eribulin following standard.
  • neoadjuvant chemotherapy and primary surgical therapy.
  • Assess the toxicity of eribulin in this patient population.

Participating Physician Clinics

  • Family Cancer Center Foundation – Walnut Grove, Bartlett, Southaven, Oxford
  • Boston Baskin Cancer Foundation – East Memphis, Bartlett, Southaven

Clinical Trial Categories

  • Breast Cancer
Sarah Cannon Research Institute Oncology Research Consortium
How to Participate

Partial Inclusion Criteria

  • Previous treatment with a minimum of 4 cycles of neoadjuvant anthracycline and/or taxane containing chemotherapy (+trastuzumab in HER2-positive patients).
  • Patients must be ≥21 days and ≤ 84 days from breast surgery and fully recovered.
  • Adequate hematologic, liver, and renal function.
  • No radiotherapy.

For the current eligibility status of this clinical study, referring physicians may call the Baptist referral line at 901-227-DOCS (3627).